Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
27.70
-0.19 (-0.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
6
Next >
3 Hot Stocks That Could Live Up to Their Lofty Valuations
December 08, 2022
These companies have long runways of growth ahead
Via
The Motley Fool
Is AbbVie Stock a Buy Now?
December 06, 2022
The pharmaceutical company prepared well as Humira approaches its patent cliff next year.
Via
The Motley Fool
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
November 29, 2022
Xenon Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 92 Tuesday, up from 89 a day earlier.
Via
Investor's Business Daily
BioCryst Pharmaceuticals Stock Sees RS Rating Rise To 84
November 11, 2022
The Relative Strength (RS) Rating for BioCryst Pharmaceuticals stock climbed into a new percentile Friday, with a rise from 64 to 84.
Via
Investor's Business Daily
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink
October 25, 2022
You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
October 21, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
HC Wainwright Is Bullish On This Multiple Myeloma Focused Stock
August 22, 2022
Via
Benzinga
Where Genmab Stands With Analysts
August 11, 2022
Genmab (NASDAQ:GMAB) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 01, 2022
During Thursday's session, 108 stocks hit new 52-week highs.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
November 25, 2022
On Friday, 68 companies reached new 52-week highs.
Via
Benzinga
Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark
October 14, 2022
In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday.
Via
Investor's Business Daily
Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates
August 05, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
November 21, 2022
During Monday's session, 50 stocks hit new 52-week highs.
Via
Benzinga
Amgen Stock Shows Market Leadership With Jump To 90 RS Rating
October 12, 2022
On Wednesday, Amgen stock hit a key technical milestone, with its Relative Strength Rating upgraded to 90, a rise from 78 the day before.
Via
Investor's Business Daily
BioCryst Pharmaceuticals Stock Shows Rising Relative Strength
October 10, 2022
On Monday, BioCryst Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 90 to 93.
Via
Investor's Business Daily
Pacira Pharmaceuticals Stock Shows Rising Relative Strength
October 07, 2022
On Friday, Pacira Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 69 to 73.
Via
Investor's Business Daily
Seagen, Zai Lab Ink Regional Strategic Licensing Agreement For Cervical Cancer Treatment
September 27, 2022
Via
Benzinga
Pain Therapeutics Stock Shows Rising Price Performance With Jump To 97 RS Rating
September 23, 2022
Pain Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.
Via
Investor's Business Daily
Akero Therapeutics Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 14, 2022
Akero Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 73 to 99.
Via
Investor's Business Daily
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade
September 09, 2022
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.
Via
Investor's Business Daily
Amylyx Pharmaceuticals Stock Sees Relative Strength Rating Rise To 98
September 09, 2022
Amylyx Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating improve to 98, up from 83 the day before.
Via
Investor's Business Daily
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
September 02, 2022
Agios Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 65 to 93.
Via
Investor's Business Daily
Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90
September 01, 2022
On Thursday, Legend Biotech stock had its Relative Strength (RS) Rating upgraded to 91, up from 87 a day earlier.
Via
Investor's Business Daily
Golden Cross Appears Before Genmab Investors
August 31, 2022
If history is any guide, there may be good fortune ahead for shares of Genmab (NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the...
Via
Benzinga
Intercept Pharmaceutical Stock Shows Market Leadership; Earns 92 RS Rating
August 30, 2022
On Tuesday, Intercept Pharmaceutical stock had its Relative Strength Rating upgraded to 92, up from 89 a day earlier.
Via
Investor's Business Daily
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating
August 25, 2022
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94.
Via
Investor's Business Daily
Kymera Therapeutics Stock Scores Rising Relative Price Strength
August 22, 2022
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.
Via
Investor's Business Daily
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022
July 18, 2022
Via
Benzinga
Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?
July 07, 2022
Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? Is AbbVie stock a buy today
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.